China · Delayed Price · Currency is CNY Enwei Pharmaceutical Statistics
Total Valuation
SHE:301331 has a market cap or net worth of CNY 2.95 billion. The enterprise value is 2.62 billion.
| Market Cap | 2.95B |
| Enterprise Value | 2.62B |
Important Dates
The next estimated earnings date is Monday, April 27, 2026.
| Earnings Date | Apr 27, 2026 |
| Ex-Dividend Date | Jan 8, 2026 |
Share Statistics
SHE:301331 has 101.08 million shares outstanding. The number of shares has decreased by -1.90% in one year.
| Current Share Class | 101.08M |
| Shares Outstanding | 101.08M |
| Shares Change (YoY) | -1.90% |
| Shares Change (QoQ) | -0.07% |
| Owned by Insiders (%) | 0.69% |
| Owned by Institutions (%) | 2.55% |
| Float | 27.63M |
Valuation Ratios
The trailing PE ratio is 56.02.
| PE Ratio | 56.02 |
| Forward PE | n/a |
| PS Ratio | 3.32 |
| PB Ratio | 2.72 |
| P/TBV Ratio | 3.42 |
| P/FCF Ratio | 89.75 |
| P/OCF Ratio | 35.28 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 25.34, with an EV/FCF ratio of 79.63.
| EV / Earnings | 50.30 |
| EV / Sales | 2.95 |
| EV / EBITDA | 25.34 |
| EV / EBIT | 52.79 |
| EV / FCF | 79.63 |
Financial Position
The company has a current ratio of 4.44, with a Debt / Equity ratio of 0.18.
| Current Ratio | 4.44 |
| Quick Ratio | 3.76 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | 1.86 |
| Debt / FCF | 5.84 |
| Interest Coverage | 15.49 |
Financial Efficiency
Return on equity (ROE) is 4.94% and return on invested capital (ROIC) is 5.38%.
| Return on Equity (ROE) | 4.94% |
| Return on Assets (ROA) | 2.12% |
| Return on Invested Capital (ROIC) | 5.38% |
| Return on Capital Employed (ROCE) | 3.86% |
| Weighted Average Cost of Capital (WACC) | 7.09% |
| Revenue Per Employee | 574,057 |
| Profits Per Employee | 33,631 |
| Employee Count | 1,548 |
| Asset Turnover | 0.61 |
| Inventory Turnover | 4.14 |
Taxes
In the past 12 months, SHE:301331 has paid 12.29 million in taxes.
| Income Tax | 12.29M |
| Effective Tax Rate | 19.10% |
Stock Price Statistics
The stock price has increased by +25.92% in the last 52 weeks. The beta is 0.58, so SHE:301331's price volatility has been lower than the market average.
| Beta (5Y) | 0.58 |
| 52-Week Price Change | +25.92% |
| 50-Day Moving Average | 28.23 |
| 200-Day Moving Average | 30.78 |
| Relative Strength Index (RSI) | 54.71 |
| Average Volume (20 Days) | 1,980,241 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, SHE:301331 had revenue of CNY 888.64 million and earned 52.06 million in profits. Earnings per share was 0.52.
| Revenue | 888.64M |
| Gross Profit | 429.57M |
| Operating Income | 49.60M |
| Pretax Income | 64.35M |
| Net Income | 52.06M |
| EBITDA | 102.06M |
| EBIT | 49.60M |
| Earnings Per Share (EPS) | 0.52 |
Balance Sheet
The company has 524.94 million in cash and 192.09 million in debt, with a net cash position of 332.85 million or 3.29 per share.
| Cash & Cash Equivalents | 524.94M |
| Total Debt | 192.09M |
| Net Cash | 332.85M |
| Net Cash Per Share | 3.29 |
| Equity (Book Value) | 1.08B |
| Book Value Per Share | 10.72 |
| Working Capital | 726.04M |
Cash Flow
In the last 12 months, operating cash flow was 83.66 million and capital expenditures -50.77 million, giving a free cash flow of 32.89 million.
| Operating Cash Flow | 83.66M |
| Capital Expenditures | -50.77M |
| Free Cash Flow | 32.89M |
| FCF Per Share | 0.33 |
Margins
Gross margin is 48.34%, with operating and profit margins of 5.58% and 5.86%.
| Gross Margin | 48.34% |
| Operating Margin | 5.58% |
| Pretax Margin | 7.24% |
| Profit Margin | 5.86% |
| EBITDA Margin | 11.48% |
| EBIT Margin | 5.58% |
| FCF Margin | 3.70% |
Dividends & Yields
This stock pays an annual dividend of 0.35, which amounts to a dividend yield of 1.20%.
| Dividend Per Share | 0.35 |
| Dividend Yield | 1.20% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 40.97% |
| Buyback Yield | 1.90% |
| Shareholder Yield | 3.13% |
| Earnings Yield | 1.76% |
| FCF Yield | 1.11% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 23, 2024. It was a forward split with a ratio of 1.48.
| Last Split Date | May 23, 2024 |
| Split Type | Forward |
| Split Ratio | 1.48 |
Scores
SHE:301331 has an Altman Z-Score of 5.79 and a Piotroski F-Score of 6.
| Altman Z-Score | 5.79 |
| Piotroski F-Score | 6 |